Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for MOMO, XENT and BOX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Tuesday, 11 June 2019 08:10 PM

Levi & Korsinsky, LLP

Topic:
5

NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

Momo Inc. (NASDAQ: MOMO)

Class Period: April 21, 2014 - April 29, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/momo-inc-loss-form?prid=1908&wire=1

About the lawsuit: Momo Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Momo's compliance procedures and controls were inadequate to prevent, inter alia, illicit financial reporting activity; (ii) Momo's social and dating app, Tantan, was materially noncompliant with PRC law and/or regulations; (iii) Tantan was consequently at an increased risk of being removed from Chinese app stores at the direction of Chinese governmental authorities; and (iv) as a result, Momo's public statements were materially false and misleading at all relevant times.

To learn more about the Momo Inc. class action contact [email protected].

Intersect ENT, Inc. (NASDAQGM: XENT)

Class Period: August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=1908&wire=1

About the lawsuit: Throughout the class period, Intersect ENT, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Intersect ENT, Inc. class action contact [email protected].

Box, Inc. (NYSE: BOX)

Class Period: November 28, 2018 - June 3, 2019
Lead Plaintiff Deadline : August 6, 2019
Join the action: https://www.zlk.com/pslra-1/box-inc-loss-form?prid=1908&wire=1

About the lawsuit: During the class period, Box, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter; (2) that, as a result, the Company's revenue would be materially impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Box, Inc. class action contact [email protected].

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
5
Back to newsroom
Back to Newsroom
Share by: